

## DAFTAR PUSTAKA

- Abbasi, S. dan Badheeb, A., 2011, Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy, *Lung Cancer Int*, **2011**, 1–4.
- Almanric, K., Marceau, N., Cantin, A., dan Bertin, É., 2017, Risk Factors for Nephrotoxicity Associated with Cisplatin, *Can. J. Hosp. Pharm.*, **70**(2), 99–106.
- American Cancer Society, 2018, Non-Small Cell Lung Cancer Signs and Symptoms, <https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/signs-symptoms.html>, 13 Maret 2019
- Ando, Y., Shimokata, T., Yasuda, Y., dan Hasegawa, Y., 2014, Carboplatin Dosing for Adult Japanese Patients, *Nagoya J. Med. Sci.*, **76**(1-2), 1–9.
- Badan Penelitian dan Pengembangan Kesehatan, 2013, Riset Kesehatan Dasar (RISKESDAS) 2013, Kementerian Kesehatan Republik Indonesia.
- Bonventre, J. V., Vaidya, V.S., Schmouder, R., Feig, P., Dieterle, F., dan 2010, Next-Generation Biomarkers for Detecting Kidney Toxicity, *Nat. Biotechnol.*, **28**(5), 436–440.
- Briguori, C., Colombo, A., Airoidi, F., Morici, N., Violante, G.M.S.A., Focaccio, A., Montorfano, M., Carlino, M., Condorelli, G., dan Ricciardelli, B., 2005, Nephrotoxicity of Low-osmolality Versus Iso-osmolality Contrast Agents: Impact of N-acetylcysteine, *Kidney Int*, **68**, 2250–2255.
- Chang, A.R., Grams, M.E., Ballew, S.H., Bilo, H., Correa, A., Evans, M., Gutierrez, O.M., Hosseinpanah, F., Iseki, K., Kenealy, T., Klein, B., Kronenberg, F., Lee, B.J., Li, Y., Miura, K., Navaneethan, S.D., Roderick, P.J., Valdivielso, J.M., Visseren, F.L.J., Zhang, L., Gansevoort, R.T., Hallan, S.I., Levey, A.S., Matsushita, K., Shalev, V., dan Woodward, M., 2019, Adiposity and Risk of Decline in Glomerular Filtration Rate: Meta-Analysis of Individual Participant Data in a Global Consortium, *BMJ*, **364**, 1–11.
- Choudhury, D. dan Ahmed, Z., 2006, Drug-associated Renal Dysfunction and Injury, *Nat. Clin. Pract. Nephrol.*, **2**(2), 80–91.
- Coco, T. dan Klasner, A., 2004, Drug-Induced Rhabdomyolysis, *Curr. Opin. Pediatr.*, **16**(2), 206–210.
- Cosaert, J. dan Quoix, E., 2002, Platinum Drugs in the Treatment of Non-Small-Cell Lung Cancer, *Br. J. Cancer*, **87**(8), 825–833.
- DiPiro, C. V., 2015, Lung Cancer, dalam Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., DiPiro, C. V. (Eds.), *Pharmacotherapy Handbook*, 642–646, Mc Graw Hill, New York.

- Duan, Z., Liu, J., Yin, P., Li, J., Cai, G., dan XM. Chen, 2018, Impact of Aging on the Risk of Platinum-Related Renal Toxicity: A Systematic Review and Meta-Analysis, *Cancer Treat. Rev.*, **69**, 243–253.
- Dzoyem, J.P., Kuete, V., dan Eloff, J.N., 2014, Biochemical Parameters in Toxicological Studies in Africa : Significance, Principle of Methods, Data Interpretation, and Use in Plant Screenings, dalam Kuete, V. (Ed.), *Toxicological Survey of African Medicinal Plants*, 659–715, Elsevier Inc.
- Ergun, I., Keven, K., Uruc, I., Ekmekci, Y., Canbakan, B., Erden, I., dan Karatan, O., 2006, The Safety of Gadolinium in Patients with Stage 3 and 4 Renal Failure, *Nephrol. Dial. Transplant.*, **21**, 697–700.
- Fukasawa, H., Furuya, R., Yasuda, H., Yamamoto, T., Hishida, A., dan Kitagawa, M., 2014, Anti-Cancer Agent-Induced Nephrotoxicity, *Anticancer. Agents Med. Chem.*, **14**(7), 921–927.
- Girard, N., Jacoulet, P., Gainet, M., Elleuch, R., Pernet, D., Depierre, A., Dalphin, J.-C., dan Westeel, V., 2009, Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine, *J. Thorac. Oncol.*, **4**(12), 1544–1549.
- Glezerman, I.G. dan Jaimes, E.A., 2016, Chemotherapy and Kidney Injury Onco-Nephrology Curric, <https://www.asn-online.org/education/distancelearning/curricula/onco>, 19 Maret 2019.
- Gridelli, C., Rossi, A., Carbone, D.P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., dan Rosell, R., 2015, Non-Small-Cell Lung Cancer, *Nat. Rev. Dis. Prim.*, **1**, 1–16.
- Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., Vinante, O., Pronzato, P., dan Pappagallo, G., 2009, Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach, *Oncologist*, **14**(5), 497–510.
- Hayati, F., Hossainzadeh, M., Shayanpour, S., Abedi-Gheshlaghi, Z., Seifollah, S., dan Mousavi, B., 2016, Prevention of Cisplatin Nephrotoxicity, *J. Nephropharmacology*, **5**(1), 57–60.
- International Agency for Resesarch on Cancer, 2012, GLOBOCAN 2012: Estimated Incidence, Mortality and Prevalence Worldwide in 2012, [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx), 14 Mei 2018.
- Izzedine, H. dan Perazella, M.A., 2017, Anticancer Drug-Induced Acute Kidney Injury, *Kidney Int. Reports*, **2**(4), 504–514.
- Jongh, F. de, Veen, R. van, Veltman, S., Wit, R. de, Burg, M. van der, Bent, M. van den, Planting, Ast., Graveland, W., Stoter, G., dan Verweij, J., 2003, Weekly High-dose Cisplatin is a Feasible Treatment Option : Analysis on Prognostic Factors for Toxicity in 400 Patients, *Br. J. Cancer*, **88**(8), 1199–1206.

- Kato, M., Shukuya, T., Mori, K., Kanemaru, R., Honma, Y., Nanjo, Y., Muraki, K., Shibayama, R., Koyama, R., Shimada, N., Takahashi, F., dan Takahashi, K., 2016, Cerebral Infarction in Advanced Non-Small Cell Lung Cancer : a Case Control Study, *BMC Cancer*, **16**(203), 1–7.
- Kidera, Y., Kawakami, H., Sakiyama, T., Okamoto, K., Tanaka, K., Takeda, M., Kaneda, H., Nishina, S.I., Tsurutani, J., Fujiwara, K., Nomura, M., Yamazoe, Y., Chiba, Y., Nishida, S., Tamura, T., dan Nakagawa, K., 2014, Risk Factors for Cisplatin-induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection, *PLoS One*, **9**(7), 1–10.
- Kim, J.H., Kim, H.S., dan Kim, B.J., 2017, Prognostic Value of Smoking Status in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors : a Meta-Analysis, *Oncotarget*, **8**(54), 93149–93155.
- Kim, S.Y. dan Moon, A., 2012, Drug-Induced Nephrotoxicity and Its Biomarkers, *Biomol. Ther.*, **20**(3), 268–272.
- Kintzel, P.E., 2001, Anticancer Drug – Induced Kidney Disorders Incidence , Prevention and Management, *Drug Saf.*, **24**(1), 19–38.
- Latcha, S., Jaimes, E.A., Patil, S., Glezerman, I.G., Mehta, S., dan Flombaum, C.D., 2016, Long – Term Renal Outcomes after Cisplatin Treatment, *Clin. J. Am. Soc. Nephrol.*, **11**(7), 1–7.
- Lemeshow, S., Hosmer Jr, D.W., Klar, J., dan Lwanga, S.K., 1990, Adequacy of Sample Size in Health Studies, John Wiley and Sons, Chichester.
- Markowitz, G.S. dan Perazella, M.A., 2005, Drug-Induced Renal Failure : a Focus on Tubulointerstitial Disease, *Clin. Chim. Acta*, **351**(1-2), 31–47.
- Mathijssen, R.H.J., de Jong, F.A., Loos, W.J., van der Bol, J.M., Verweij, J., dan Sparreboom, A., 2007, Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?, *Oncologist*, **12**, 913–923.
- McCune, J.S. dan Frieze, D.A., 2008, Lung Cancer, dalam DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.), *Pharmacotherapy A Pathophysiologic Approach*, 2157–2175, Mc Graw Hill, New York.
- McElnay, P. dan Lim, E., 2014, Adjuvant or Neoadjuvant Chemotherapy for NSCLC, *J. Thorac. Dis.*, **6**(S2), 224–227.
- Miller, R.P., Tadagavadi, R.K., Ramesh, G., dan Reeves, W.B., 2010, Mechanisms of Cisplatin Nephrotoxicity, *Toxins (Basel)*, **2**(11), 2490–2518.
- Miyoshi, T., Misumi, N., Hiraike, M., Mihara, Y., Nishino, T., Tsuruta, M., Kawamata, Y., Hiraki, Y., Kozono, A., dan Ichiki, M., 2016, Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer, *Biol. Pharm. Bull*, **39**(12), 2009–2014.

- Mizuno, T., Ishikawa, K., Sato, W., Koike, T., Kushida, M., Miyagawa, Y., Yamada, K., Hirata, S., Imai, E., dan Noda, Y., 2013, The Risk Factors of Severe Acute Kidney Injury Induced by Cisplatin, *Oncology*, **85**(6), 364–369.
- Mohri, J., Katada, C., Ueda, M., Sugawara, M., Yamashita, K., Moriya, H., Komori, S., Hayakawa, K., Koizumi, W., dan Atsuda, K., 2018, Predisposing Factors for Chemotherapy-Induced Nephrotoxicity in Patients with Advanced Esophageal Cancer Who Received Combination Chemotherapy with Docetaxel, Cisplatin, and 5-fluorouracil, *J. Transl. Intern. Med.*, **6**(1), 32–37.
- Monleón, A.V., Barrallo, I.G., dan González, I.C., 2017, Cisplatin Nephrotoxicity in A Patient With Metastatic Testicular Choriocarcinoma : A Case Report and Review of the Literature, *Kidney Dis. Transplant.*, **1**(1), 1–5.
- Muraki, K., Koyama, R., Honma, Y., Yagishita, S., Shukuya, T., Ohashi, R., Takahashi, F., Kido, K., Iwakami, S.I., Sasaki, S., Iwase, A., dan Takahashi, K., 2012, Hydration with Magnesium and Mannitol without Furosemide Prevents the Nephrotoxicity Induced by Cisplatin and Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer, *J. Thorac. Dis.*, **4**(6), 562–568.
- National Comprehensive Cancer Network, 2014, Non-Small Cell Lung Cancer, NCCN Guidel. Version 7.2015 Non-Small Cell Lung Cancer, 1–98.
- Naughton, C.A., 2008, Drug-Induced Nephrotoxicity, *Am. Fam. Physician*, **78**(6), 743–750.
- Nematbakhsh, M., Pezeshki, Z., Jazi, F.E., Mazaheri, B., Moeini, M., Safari, T., Azarkish, F., Moslemi, F., Rezaei, A., Saberi, S., Dehghani, A., Malek, M., Ghasemi, M., Zeinali, F., Zamani, Z., Navidi, M., Jilanchi, S., Shirdavani, S., dan Ashrafi, F., 2017, Cisplatin-Induced Nephrotoxicity ; Protective Supplements and Gender Differences, *Asian Pacific J Cancer Prev.*, **18**(2), 295–314.
- Nolin, T.D., Himmelfarb, J., 2008, Drug-Induced Kidney Disease, dalam DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.), *Pharmacotherapy A Pathophysiologic Approach*, 795–810, Mc Graw Hill, New York.
- Perazella, M.A., 2005, Drug-Induced Nephropathy : an Update, *Expert Opin. Drug Saf.*, **4**(4), 689–706.
- Perazella, M.A., 2009, Renal Vulnerability to Drug Toxicity, *Clin. J. Am. Soc. Nephrol.*, **4**(7), 1275–1283.
- Perazella, M.A., 2012, Drug Use and Nephrotoxicity in the Intensive Care Unit, *Kidney Int.*, **81**, 1172–1178.
- Perazella, M.A., 2018, Pharmacology behind Common Drug Nephrotoxicities, *Clin. J. Am. Soc. Nephrol.*, **13**(12), 1897–1908.

- Peres, L.A.B. dan Cunha Júnior, A.D. da, 2013, Acute Nephrotoxicity of Cisplatin: Molecular Mechanisms, *J. Bras. Nefrol.*, **35**(4), 332–340.
- Pérez-ramírez, C., Ahmed, M.C., Eduardo, A., Javier, V., José, M., dan Ángel, F.M., 2018, Pharmacogenetics of Platinum-Based Chemotherapy : Impact of DNA Repair and Folate Metabolism Gene Polymorphisms on Prognosis of Non-Small Cell Lung Cancer Patients, *Pharmacogenomics J.*, **19**(2), 164–177.
- Pircher, A., Wasle, I.K., Mian, M., Gamerith, G., Ulsperger, E., Studnicka, M., Mohn-staudner, A., Hilbe, W., dan Fiegl, M., 2013, Docetaxel in the Treatment of Non-Small Cell Lung Cancer ( NSCLC ) – An Observational Study Focusing on Symptom Improvement, *Anticancer Res.*, **33**(9), 3831–3836.
- Pisoni, R., Ruggenenti, P., dan Remuzzi, G., 2001, Drug-Induced Thrombotic Microangiopathy Incidence, Prevention and Management, *Drug Saf.*, **24**(7), 491–501.
- Prasaja, Y., Sutandyo, N., dan Andrajati, R., 2015, Incidence of Cisplatin-Induced Nephrotoxicity and Associated Factors among Cancer Patients in Indonesia, *Asian Pacific J. Cancer Prev.*, **16**(3), 1117–1122.
- Saad, S.Y., Najjar, T.A.O., Noreddin, A.M., dan Ammar, C., 2001, Effects of Gemcitabine on Cisplatin-Induced Nephrotoxicity in Rats: Schedule-Dependent Study, *Pharmacol. Res.*, **43**(2), 193–19.
- Schetz, M., Dasta, J., Goldstein, S., dan Golper, T., 2005, Drug-Induced Acute Kidney Injury, *Curr. Opin. Crit. Care*, **11**, 555–565.
- Shinke, H., Masuda, S., Togashi, Y., Ikemi, Y., Ozawa, A., Sato, T., Kim, Y.H., Mishima, M., Ichimura, T., V., J., Bonventre, dan Matsubara, K., 2015, Urinary Kidney Injury Molecule-1 and Monocyte Chemotactic Protein-1 are Noninvasive Biomarkers of Cisplatin-induced Nephrotoxicity in Lung Cancer Patients, *Cancer Chemother Pharmacol.*, **76**(5), 989–996.
- Singh, N., Ganguli, A., Prakash, A., 2003, Drug-induced Kidney Diseases, *J. Assoc. Physicians India*, **51**, 970–979.
- Tezcan, S., Izzettin, F.V., Sancar, M., Yumuk, P.F., dan Turhal, S., 2013, Nephrotoxicity Evaluation in Outpatients Treated with Cisplatin-Based Chemotherapy Using a Short Hydration Method, *Pharmacol. Pharm.*, **4**, 296–302.
- Thomas, C., Thomas, L., 2009, Renal Failure - Measuring the Glomerular Filtration Rate, *Dtsch. Ärzteblatt Int.*, **106**(51-52), 849–854.
- Tiseo, M., Martelli, O., Mancuso, A., Sormani, M.P., Bruzzi, P., Salvia, R. Di, Marinis, F. De, dan Ardizzoni, A., 2007, Short Hydration Regimen And Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy For Outpatient Treatment in Lung Cancer And Mesothelioma, *Tumori J.*, **93**(2), 138–144.

- Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-tieulent, J., dan Jemal, A., 2015, Global Cancer Statistics 2012, *CA a cancer J. Clin.*, **65**(2), 87–108.
- Wakelee, H., Kelly, K., Edelman, dan M.J., 2016, 50 Years of Progress in the Systemic Therapy of Non-small Cell Lung Cancer, *HHS Public Access*, **2014**, 1–28.
- Wang, C., Guo, M., Zhang, N., dan Wang, G., 2018, Association of Body Mass Index and Outcomes Following Lobectomy for Non-Small-Cell Lung Cancer, *World J. Surg. Oncol.*, **16**(1), 1–8.
- Wheate, N.J., Walker, S., Craig, G.E., dan Oun, R., 2010, The Status of Platinum Anticancer Drugs in the Clinic and in Clinical Trials, *Dalt. Trans.*, **39**(35), 8113–8127.
- Yamamoto, Y., Watanabe, K., Matsushita, H., Tsukiyama, I., Matsuura, K., dan Wakatsuki, A., 2017, Multivariate Analysis of Risk Factors for Cisplatin-induced Nephrotoxicity in Gynecological Cancer, *J. Obstet. Gynaecol. Res.*, **43**(12), 1880–1886.